GSK Contracted to Produce World’s First Malaria Vaccine

Pharmaceutical company GSK has been awarded a contract to produce the world’s first malaria vaccine so that millions more children will be protected against the killer disease.

The landmark award, valued at up to USD 170 million, will lead to 18 million doses of the RTS,S vaccine being available over the next three years, potentially saving thousands of young lives annually. The RTS,S malaria vaccine – the result of 35 years of research and development – is the first-ever vaccine against a parasitic disease.

It was launched in a 2019 pilot programme, coordinated by WHO, in three countries – Ghana, Kenya and Malawi – which has reached more than 800,000 children. Last October, the UN health agency recommended its widespread use in countries with moderate to high malaria transmission.

The disease which is caused by parasites and transmitted to humans through infected female Anopheles mosquitoes remains one of the biggest killers of children under five. In 2020, nearly half a million boys and girls died from the disease in Africa alone, a rate of one death every minute.

More than 30 countries have areas with moderate to high malaria transmission, according to data from the World Health Organization (WHO), and the vaccine could provide added protection to more than 25 million children each year once the supply ramps up.

Etleva Kadilli, Director of UNICEF’s Supply Division, said the rollout sends a clear message to malaria vaccine developers to continue their work. “We hope this is just the beginning. Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market,” she said.

Gavi, the Vaccine Alliance, has already announced a decision to provide funding for malaria vaccine programmes in eligible countries, opening the pathway for a broader roll-out of the vaccine.

“Thanks to UNICEF’s procurement work, we now have more certainty on supply and can move a step further towards getting this life-saving vaccine to the people who need it the most. As manufacturing ramps up over time, we hope that increasing volumes will also lead to more sustainable, lower prices,” according to GAVI CEO Seth Barkley.

Meanwhile, WHO has welcomed progress in securing supply and timely access to the vaccine so that more countries can introduce it as soon as possible.

“Lives are at stake, every day,” said Dr Kate O’Brien, Director of WHO’s Department of Immunization, Vaccines and Biologicals. “Given the initial limited supply, it is crucial that children living in areas where the risk of disease and need is highest are prioritized first”.

UNICEF expects that the demand for the malaria vaccine will be high among affected countries. As with any new vaccine, supply will be limited at first, the agency said but will increase as manufacturing capacity ramps up over time, which in turn will lead to a decrease in costs per dose. 

Plans are already underway to boost production, including through technology transfer, UNICEF added, “so that every child at risk will one day have the opportunity to be immunized against this killer disease”.